A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 9651 participants.

Also called NCT03914326

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 9,651 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03914326
  • EudraCT 2018-003141-42
Other papers using this trial's data
  • Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial Diabetes care, 2026-02-01 DOI, PubMed 41380027, PMC12824789 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes The New England journal of medicine, 2025-05-29 DOI, PubMed 40162642
  • Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial Circulation, 2025-06-10 DOI, PubMed 40156843, PMC12144549 In the PMC Open Access subset under CC BY-NC-ND.
  • Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial JAMA cardiology, 2026-05-01 DOI, PubMed 41879791, PMC13019341 In the PMC Open Access subset under CC BY-NC-ND.
  • Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial JAMA internal medicine, 2026-04-01 DOI, PubMed 41627802, PMC12865694 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Algeria, Argentina, Austria, Belgium, Brazil, Canada, China, Colombia, Croatia, Czechia, Denmark, France, Germany, Hong Kong SAR China, India, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03914326. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-17 (actual); primary completion 2024-08-23 (actual). Results posted on 2025-09-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
Acronym
SOUL
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo (semaglutide)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03914326
Content hash
15d016496adbee58826826543b8e9c75aff8ca6239423e68e455f6cfa2ae92af